<DOC>
	<DOCNO>NCT00484198</DOCNO>
	<brief_summary>This 26-week , multicenter , randomize , double-blind , placebo active comparator ( Pioglitazone ) -controlled , parallel-group study subject type 2 diabetes currently sub-optimally control diet exercise non-thiazolidinedione antihyperglycemic monotherapy . The total duration subject 's participation approximately 30 week , include 2-week placebo run-in period , 26-week double-blind treatment period , 2-week post-treatment follow-up period .</brief_summary>
	<brief_title>Randomized , Double-Blind Active Comparator-Controlled Study Rivoglitazone Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosis type 2 diabetes Male female least 18 year age A1C &gt; 7 % less equal 8.5 % Nonfasting Cpeptide &gt; 0.5ng/mL Current monotherapy treatment stable dose approve nonTZD antihyperglycemic medication great equal 3 month prior screen Untreated antihyperglycemic agent 2 month prior screen History type 1 diabetes ketoacidosis History longterm therapy insulin BMI &gt; 45 kg/m2 Known history CHF Impaired hepatic function History prior treatment failure , intolerance , TZD Contraindication treatment pioglitazone Treatment fibrates If untreated oral antihyperglycemic , consider fail diet exercise modification sole treatment type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>